The company believes its new combination technology can make insulin injections a thing of the past.
New devices are coming, but the real advances will involve combinations.
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
A day after Lilly’s strong clinical showing in obesity, Novo comes out swinging.
Tirzepatide is coming for Wegovy’s crown – and maybe faster than expected.
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.